KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Accumulated Expenses (2018 - 2025)

Amneal Pharmaceuticals has reported Other Accumulated Expenses over the past 7 years, most recently at $43.3 million for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $43.3 million for Q4 2025, up 36.22% from a year ago — trailing twelve months through Dec 2025 was $43.3 million (up 36.22% YoY), and the annual figure for FY2025 was $43.3 million, up 36.22%.
  • Other Accumulated Expenses for Q4 2025 was $43.3 million at Amneal Pharmaceuticals, up from $40.6 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for AMRX hit a ceiling of $275.3 million in Q2 2022 and a floor of $30.1 million in Q1 2024.
  • Median Other Accumulated Expenses over the past 5 years was $50.8 million (2021), compared with a mean of $76.0 million.
  • Biggest five-year swings in Other Accumulated Expenses: skyrocketed 85.32% in 2022 and later plummeted 72.03% in 2023.
  • Amneal Pharmaceuticals' Other Accumulated Expenses stood at $58.0 million in 2021, then skyrocketed by 85.32% to $107.5 million in 2022, then decreased by 28.37% to $77.0 million in 2023, then crashed by 58.75% to $31.8 million in 2024, then surged by 36.22% to $43.3 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $43.3 million (Q4 2025), $40.6 million (Q3 2025), and $41.5 million (Q2 2025) per Business Quant data.